Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner

Cytotherapy

Volumn 12, Issue 3, 2010, Pages 361-370

  Joo, Sun Young ^a   Cho, Kyung Ah ^a   Jung, Yun Jae ^b   Kim, Han Seong ^c   Park, Seong Yeol ^d   Choi, Yong Bock ^d   Hong, Kyeong Man ^d   Woo, So Youn ^a   Seoh, Ju Young ^a   Cho, Su Jin ^a   Ryu, Kyung Ha ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Gachon University   (South Korea)

^c Inje University   (South Korea)

^d National Cancer Center   (South Korea)

Author keywords

Graft versus host disease; Mesenchymal stromal cells; Mouse model; Optimal dose

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; GROWTH INHIBITION; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; SURVIVAL RATE; THYMOCYTE;

EID: 77950550604     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240903502712     Document Type: Article

References (34)

1. Hiemenz JW. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2009;46:289-312.
2. Ye Z, Wang Y, Xie HY, Zheng SS. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int. 2008;7: 608-614
3. Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008;42(Suppl 1):S66-9.
4. Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol. 2006;57:225-244
5. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371-4383
6. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170 (Pubitemid 46697905)
7. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815-1822 (Pubitemid 40223708)
8. Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des. 2009;15:1974-1997
9. Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med. 2001;52:353-370 (Pubitemid 32195330)
10. Zhao RC, Liao L, Han Q. Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy. J Lab Clin Med. 2004;143:284-291 (Pubitemid 38586493)
11. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Identifi cation of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 2007;13:217-226
12. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrowderived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251:131-136
13. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A, et al. Megadose transplantation of purifi ed peripheral blood CD34(+) progenitor cells from HLAmismatched parental donors in children. Bone Marrow Transplant. 2001;27:777-783
14. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infi ltration of T-cell subsets. Blood. 2005;106:1113-1122 (Pubitemid 41076462)
15. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003; 9:1144-1150
16. Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Fili C, et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after Allo-SCT: results of a prospective study. Bone Marrow Transplant. 2009;44:729-737
17. Reddy V, Winer AG, Eksioglu E, Meier-Kriesche HU, Schold JD, Wingard JR. Interleukin 12 is associated with reduced relapse without increased incidence of graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11: 1014-1021
18. Jeong DC, Han CW, Jin JY, Kim DS, Choi IB, Kim WI, et al. Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility. Exp Hematol. 1999;27:1219-1225
19. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood. 1996; 88:3230-3239
20. Fukui J, Inaba M, Ueda Y, Miyake T, Hosaka N, Kwon AH, et al. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells. Stem Cells. 2007;25: 1595-1601 (Pubitemid 47106030)
21. Desbarats J, Seemayer TA, Lapp WS. Irradiation of the skin and systemic graft-versus-host disease synergize to produce cutaneous lesions. Am J Pathol. 1994;144:883-888 (Pubitemid 24160629)
22. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292:895-902.
23. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, et al. Suppression of graft-versus-host disease and amplifi cation of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101:1835-1842
24. Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L, et al. Human adipose-derived mesenchymal stem cells reduce infl ammatory and T-cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241-248
25. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933-3946
26. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36:309-318 (Pubitemid 351221170)
27. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferongamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353-363 (Pubitemid 47063057)
28. Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev. 2008;7:370-375
29. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin- 6-dependent mechanism. Stem Cells. 2007;25:2025-2032 (Pubitemid 47258180)
30. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett. 2008;115:50-58 (Pubitemid 350298590)
31. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15:42-49
32. Najar M, Rouas R, Raicevic G, Id Boufker H, Lewalle P, Meuleman N, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy. 2009;11:570-583
33. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21:1992-1999 (Pubitemid 47299975)
34. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA. Coblockade of the LFA1:ICAM and CD28/ CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood. 1995;85:2607-2618